Aclaris Therapeutics(ACRS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ACRS Aclaris Therapeutics

Trading 03-02 15:51:26 EST

3.07

+0.20

+6.97%

High3.11	Low2.75	Vol4.63M
Open2.83	D1 Closing2.87	Amplitude12.58%
Mkt Cap370.23M	Tradable Cap289.38M	Total Shares120.60M
T/O13.57M	T/O Rate4.91%	Tradable Shares94.26M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"ACRS","market":"US","secType":"STK","nameCN":"Aclaris Therapeutics","latestPrice":3.07,"timestamp":1772484679762,"preClose":2.87,"halted":0,"volume":4626417,"delay":0,"changeRate":0.06968641114982568,"floatShares":94259700,"shares":120595189,"eps":-0.53,"marketStatus":"Trading","change":0.2,"latestTime":"03-02 15:51:26 EST","open":2.83,"high":3.111,"low":2.75,"amount":13566761.0516601,"amplitude":0.125784,"askPrice":3.08,"askSize":22215,"bidPrice":3.07,"bidSize":1428,"shortable":3,"etf":0,"ttmEps":-0.53,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1772485200000},"marketStatusCode":2,"adr":0,"adrRate":0,"listingDate":1444190400000,"exchange":"NASDAQ","adjPreClose":2.87,"preHourTrading":{"tag":"盘前","latestPrice":2.87,"preClose":2.87,"latestTime":"08:27 EST","volume":32,"amount":91.84,"timestamp":1772458032311,"change":0,"changeRate":0,"amplitude":0},"postHourTrading":{"tag":"盘后","latestPrice":2.9,"preClose":2.87,"latestTime":"19:11 EST","volume":163100,"amount":473139.53,"timestamp":1772237484925,"change":0.03,"changeRate":0.010453,"amplitude":0.073171},"volumeRatio":3.060752,"impliedVol":1.1793,"impliedVolPercentile":0.3705},"requestUrl":"/m/hq/s/ACRS","defaultTab":"news","newsList":[{"id":"2614832984","title":"Calendar of U.S. Earnings Expected in the Week Ahead","url":"https://stock-news.laohu8.com/highlight/detail?id=2614832984","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614832984?lang=en_us&edition=fundamental","pubTime":"2026-02-27 19:00","pubTimestamp":1772190000,"startTime":"0","endTime":"0","summary":"Major companies tentatively scheduled to report quarterly earnings in the week ahead, with earnings estimates provided by FactSet Research Systems Inc.·Arbor Realty Tr                                  4Q       .13   8:30 AM. ·Delek US Hldgs                                    4Q      (.19)  7:00 AM. ·NW Natural Hldg                                  4Q      1.36   6:00 AM","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AMRC","ALXO","ASAN","ALG","ASTH","CERS","LIF","CLMT","STNE","AZO","CRD.A","AAON","ADT","AMWD","CRC","ABR","AMRX","BLTE","ATRA","ARCT","ANIP","CGEN","BRCB","ACEL","CVEO","BBY","CMPX","ACRS","BEEP","AMR","AMLX","CRD.B","BRK.A","NPCE","BGS","CRCT","BCYC","ACHR","CXDO","CRI","BOX","ANTA","BRK.B","BTSG","CORZ","GSAT"],"gpt_icon":1},{"id":"2614237030","title":"Craig-Hallum Sticks to Its Buy Rating for Aclaris Therapeutics (ACRS)","url":"https://stock-news.laohu8.com/highlight/detail?id=2614237030","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614237030?lang=en_us&edition=fundamental","pubTime":"2026-02-26 22:56","pubTimestamp":1772117779,"startTime":"0","endTime":"0","summary":"In a report released today, Adam Vogel from Craig-Hallum reiterated a Buy rating on Aclaris Therapeutics, with a price target of $10.00. Vogel cove...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/craig-hallum-sticks-to-its-buy-rating-for-aclaris-therapeutics-acrs-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/craig-hallum-sticks-to-its-buy-rating-for-aclaris-therapeutics-acrs-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ACRS"],"gpt_icon":0},{"id":"2614041875","title":"Aclaris Therapeutics reports Q4 EPS (16c), consensus (14c)","url":"https://stock-news.laohu8.com/highlight/detail?id=2614041875","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614041875?lang=en_us&edition=fundamental","pubTime":"2026-02-26 20:30","pubTimestamp":1772109002,"startTime":"0","endTime":"0","summary":"Reports Q4 revenue $1.3M, consensus $2.07M. Believes that its cash, cash equivalents and marketable securities will be sufficient to fund its opera...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/aclaris-therapeutics-reports-q4-eps-16c-consensus-14c-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/aclaris-therapeutics-reports-q4-eps-16c-consensus-14c-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ACRS"],"gpt_icon":0},{"id":"2614046960","title":"Aclaris Therapeutics Q4 EPS $(0.16) Misses $(0.14) Estimate, Sales $1.295M Miss $1.938M Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2614046960","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614046960?lang=en_us&edition=fundamental","pubTime":"2026-02-26 20:14","pubTimestamp":1772108055,"startTime":"0","endTime":"0","summary":"Aclaris Therapeutics (NASDAQ:ACRS) reported quarterly losses of $(0.16) per share which missed the analyst consensus estimate of $(0.14) by 11.11 percent. This is a 60 percent decrease over losses of $(0.10) per share","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/02/50882936/aclaris-therapeutics-q4-eps-0-16-misses-0-14-estimate-sales-1-295m-miss-1-938m-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ACRS"],"gpt_icon":0},{"id":"2614045010","title":"Aclaris Q4 loss narrows, but misses analysts' expectations","url":"https://stock-news.laohu8.com/highlight/detail?id=2614045010","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614045010?lang=en_us&edition=fundamental","pubTime":"2026-02-26 20:06","pubTimestamp":1772107577,"startTime":"0","endTime":"0","summary":"Aclaris Q4 loss narrows, but misses analysts' expectationsOverviewBiopharmaceutical firm Aclaris Q4 revenue and net loss missed analyst expectationsCompany reported a net loss of $19.8 mln for Q4 2025","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260226:nL1N3ZM0KX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ACRS"],"gpt_icon":0},{"id":"2614430030","title":"BRIEF-Aclaris Therapeutics Q4 Net Income USD -19.795 Million Vs. IBES Estimate USD -17.6 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2614430030","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614430030?lang=en_us&edition=fundamental","pubTime":"2026-02-26 19:58","pubTimestamp":1772107125,"startTime":"0","endTime":"0","summary":"BRIEF-Aclaris Therapeutics Q4 Net Income USD -19.795 Million Vs. IBES Estimate USD -17.6 Million\n\n\nFeb 26 (Reuters) - Aclaris Therapeutics Q4 revenue USD 1.295 million vs. IBES estimate USD 2.07 million.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260226:nPLX089B5C:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ACRS","BK4007"],"gpt_icon":0},{"id":"2614041713","title":"Aclaris Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2614041713","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614041713?lang=en_us&edition=fundamental","pubTime":"2026-02-26 19:58","pubTimestamp":1772107080,"startTime":"0","endTime":"0","summary":"- Positive Interim Results of Phase 1a Single (SAD) and Multiple Ascending Dose (MAD) Trial of Anti-TSLP/IL-4Rα Bispecific Antibody ATI-052 Support Rapid Clinical Advancement; Complete Top Line Result","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/02/26/3245403/37216/en/Aclaris-Therapeutics-Reports-Fourth-Quarter-and-Full-Year-2025-Financial-Results-and-Provides-Corporate-Update.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1169589451.USD","BK4588","BK4023","BK4218","IND","ACRS","BK4132","BK4181","AD","PD","PK","LU1169590202.USD","BK4153","AA","BK4007","BK4585"],"gpt_icon":0},{"id":"2613716653","title":"BRIEF-Aclaris Therapeutics Initiates Phase 1B Proof-Of-Concept Trial Of Its Novel Bispecific Anti-Tslp/Il-4Rα Antibody Ati-052","url":"https://stock-news.laohu8.com/highlight/detail?id=2613716653","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613716653?lang=en_us&edition=fundamental","pubTime":"2026-02-24 20:18","pubTimestamp":1771935502,"startTime":"0","endTime":"0","summary":"BRIEF-Aclaris Therapeutics Initiates Phase 1B Proof-Of-Concept Trial Of Its Novel Bispecific Anti-Tslp/Il-4Rα Antibody Ati-052Feb 24 (Reuters) - Aclaris Therapeutics Inc ACRS.O:ACLARIS THERAPEUTICS IN","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260224:nTUA5ND25V:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ACRS"],"gpt_icon":0},{"id":"2613156417","title":"Aclaris Initiates Phase 1b Asthma Trial of Bispecific Antibody ATI-052","url":"https://stock-news.laohu8.com/highlight/detail?id=2613156417","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613156417?lang=en_us&edition=fundamental","pubTime":"2026-02-24 20:01","pubTimestamp":1771934516,"startTime":"0","endTime":"0","summary":"Aclaris Therapeutics Inc. has initiated a randomized, double-blind, placebo-controlled Phase 1b proof-of-concept trial evaluating ATI-052, an investigational bispecific anti-TSLP/IL-4Rα antibody, in approximately 16 asthma patients on GINA steps 2–4 therapy prior to screening. The study will assess safety, tolerability, pharmacokinetics, pharmacodynamic biomarkers , and efficacy measures such as FEV1. The company said top-line results from this asthma trial and an ongoing Phase 1b proof-of-concept trial in atopic dermatitis are expected in the second half of 2026.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260224:nNDL3YW1V:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014005.SGD","LU2210150020.SGD","SG9999014021.USD","LU0314104364.USD","IE00BKPKM429.USD","ACRS","BK4588","LU2210149790.SGD","LU2095319765.USD","NDAQ","SG9999014013.SGD","SG9999014039.USD","IE00B64PRP62.GBP","BK4112","BK4585","IE00BGHQF748.EUR","BK4007","IE00B3QW5Z07.USD"],"gpt_icon":0},{"id":"2613771535","title":"Aclaris Therapeutics Initiates Phase 1B Proof-of-Concept Trial in Patients With Asthma With Its Novel Bispecific Anti-Tslp/Il-4RΑ Antibody ATI-052","url":"https://stock-news.laohu8.com/highlight/detail?id=2613771535","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613771535?lang=en_us&edition=fundamental","pubTime":"2026-02-24 20:00","pubTimestamp":1771934401,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260224:nTUA5ND25V:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","ACRS"],"gpt_icon":0},{"id":"2613715715","title":"Aclaris Therapeutics Inc - Phase 2B Program Encompassing Asthma and Atopic Dermatitis Expected to Start in H2 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2613715715","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613715715?lang=en_us&edition=fundamental","pubTime":"2026-02-24 20:00","pubTimestamp":1771934401,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260224:nTUA5ND25V:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","ACRS"],"gpt_icon":0},{"id":"2613715259","title":"Aclaris Therapeutics Inc - Top Line Results Expected in Second Half of 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2613715259","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613715259?lang=en_us&edition=fundamental","pubTime":"2026-02-24 20:00","pubTimestamp":1771934401,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260224:nTUA5ND25V:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ACRS","BK4007"],"gpt_icon":0},{"id":"2613578082","title":"Aclaris Therapeutics Inc  expected to post a loss of 15 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2613578082","media":"Reuters","labels":["dataReport","preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613578082?lang=en_us&edition=fundamental","pubTime":"2026-02-23 22:13","pubTimestamp":1771855988,"startTime":"0","endTime":"0","summary":"Aclaris Therapeutics Inc  expected to post a loss of15cents a share - Earnings Preview Aclaris Therapeutics Inc ACRS.OQ ACRS.O is expected to  show a fall in quarterly revenue when it reports  results","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260223:nL8N3ZJ1C8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ACRS"],"gpt_icon":0},{"id":"2608366839","title":"Aclaris Therapeutics to Present at Major Healthcare Conferences","url":"https://stock-news.laohu8.com/highlight/detail?id=2608366839","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608366839?lang=en_us&edition=fundamental","pubTime":"2026-02-04 20:00","pubTimestamp":1770206452,"startTime":"0","endTime":"0","summary":"Aclaris Therapeutics Inc. will participate in two healthcare conferences in February 2026. On February 12, 2026, Chief Executive Officer Dr. Neal Walker and senior leaders will join a fireside chat at the Guggenheim Emerging Outlook: Biotech Summit 2026 in New York. On February 26, 2026, President and COO Hugh Davis, Ph.D., will deliver a corporate presentation at the virtual Oppenheimer 36th Annual Healthcare Life Sciences Conference. Live and archived webcasts of both events will be available on the company's website.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aclaris Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire  on February 04, 2026, and is solely responsible for the informa","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260204:nNDLZ3Sy9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014005.SGD","LU2210150020.SGD","SG9999014021.USD","LU0314104364.USD","IE00BKPKM429.USD","ACRS","BK4588","LU2210149790.SGD","LU2095319765.USD","NDAQ","SG9999014013.SGD","SG9999014039.USD","IE00B64PRP62.GBP","BK4112","BK4585","IE00BGHQF748.EUR","BK4007","IE00B3QW5Z07.USD"],"gpt_icon":0},{"id":"2608369077","title":"Aclaris Therapeutics to Participate in Two February Healthcare Conferences","url":"https://stock-news.laohu8.com/highlight/detail?id=2608369077","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608369077?lang=en_us&edition=fundamental","pubTime":"2026-02-04 20:00","pubTimestamp":1770206400,"startTime":"0","endTime":"0","summary":"WAYNE, Pa., Feb.  04, 2026  (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflamma","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/02/04/3231905/37216/en/Aclaris-Therapeutics-to-Participate-in-Two-February-Healthcare-Conferences.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LABU","HCSG","XLV","BK4581","LU0128526141.USD","XBI","BK4585","LU0029874061.USD","BK4137","BK4007","BK4588","ACRS"],"gpt_icon":0},{"id":"2606466714","title":"Aclaris Therapeutics Price Target Maintained With a $16.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2606466714","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606466714?lang=en_us&edition=fundamental","pubTime":"2026-01-28 21:51","pubTimestamp":1769608260,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ACRS/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  January 28, 2026 08:51 ET (13:51 GMT)","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ACRS"],"gpt_icon":0},{"id":"2606734134","title":"Aclaris Hair Loss Drug Shows Faster Results Than Pfizer's Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2606734134","media":"Benzinga_recent_news","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606734134?lang=en_us&edition=fundamental","pubTime":"2026-01-28 02:12","pubTimestamp":1769537520,"startTime":"0","endTime":"0","summary":"Aclaris Therapeutics reported early study results showing its ATI-2138 drug drove rapid and lasting hair regrowth, outperforming Pfizer's Litfulo in a severe hair loss mouse model.","market":"hk","thumbnail":"https://cdn.benzinga.com/files/images/story/2026/01/27/Balding-Man-Showing-His-Head-With-Thin-H.jpeg?optimize=medium&dpr=2&auto=webp&width=240","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2026/01/27/Balding-Man-Showing-His-Head-With-Thin-H.jpeg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/news/health-care/26/01/50167819/aclaris-hair-loss-drug-shows-faster-results-than-pfizers-drug","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/health-care/26/01/50167819/aclaris-hair-loss-drug-shows-faster-results-than-pfizers-drug","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_recent_news","symbols":["IE0002270589.USD","SG9999001176.USD","BK4568","SG9999002232.USD","BK4534","LU0868494617.USD","LU1057294990.SGD","LU1894683264.USD","LU0321505868.SGD","BK4599","LU0225284248.USD","SG9999001176.SGD","LU0122379950.USD","BK4588","IE00BLSP4452.SGD","SG9999013999.USD","LU0058720904.USD","IE00B19Z3581.USD","BK4533","LU0289739699.SGD","LU1023059063.AUD","ACRS","BK4550","LU0321505439.SGD","IE00B19Z3B42.SGD","BK4585","SG9999011175.SGD","BK4217","IE00BBT3K403.USD","SGXZ57979304.SGD","LU0170899867.USD","BK4007","LU1883839398.USD","LU1066053197.SGD","LU0985481810.HKD","BK4592","LU1894683348.USD","LU0234572021.USD","LU0306806265.USD","IE00BLSP4239.USD","SG9999002224.SGD","BK4153","BK4581","SG9999003800.SGD","LU0306807586.USD","LU1066051498.USD","LU0456855351.SGD","IE000M9KFDE8.USD","LU0225771236.USD"],"gpt_icon":1},{"id":"2606893577","title":"Aclaris Therapeutics reports ‘positive’ results from ATI-2138","url":"https://stock-news.laohu8.com/highlight/detail?id=2606893577","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606893577?lang=en_us&edition=fundamental","pubTime":"2026-01-27 20:01","pubTimestamp":1769515300,"startTime":"0","endTime":"0","summary":"Aclaris Therapeutics (ACRS) announced recent positive preclinical results from its potent and selective ITK/JAK3 inhibitor ATI-2138 in a murine mod...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/aclaris-therapeutics-reports-positive-results-from-ati-2138-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/aclaris-therapeutics-reports-positive-results-from-ati-2138-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4187","ATI","ACRS","IE00B19Z4B17.USD","IE00B66KJ199.SGD","LU1878469433.USD","LU2065731478.USD","BK4006","IE00B7SZL793.SGD","BK4007","IE0031619046.USD"],"gpt_icon":0},{"id":"2606173786","title":"Aclaris Therapeutics Inc - to Initiate Phase 2B Trial for ATI-2138 in First Half of 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2606173786","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606173786?lang=en_us&edition=fundamental","pubTime":"2026-01-27 19:55","pubTimestamp":1769514910,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260127:nFWN3YS0MQ:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","ACRS"],"gpt_icon":0},{"id":"2606067786","title":"Aclaris Therapeutics’ Novel ITK/JAK3 Inhibitor ATI-2138 Demonstrates Rapid and Sustained Hair Regrowth in Validated Murine Model of Alopecia Areata (AA)","url":"https://stock-news.laohu8.com/highlight/detail?id=2606067786","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606067786?lang=en_us&edition=fundamental","pubTime":"2026-01-27 19:55","pubTimestamp":1769514900,"startTime":"0","endTime":"0","summary":"- ATI-2138 Outperforms Ritlecitinib in Reversal Model of Alopecia Universalis, the Most Severe AA Phenotype - WAYNE, Pa., Jan.  27, 2026  (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS),","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/01/27/3226283/37216/en/Aclaris-Therapeutics-Novel-ITK-JAK3-Inhibitor-ATI-2138-Demonstrates-Rapid-and-Sustained-Hair-Regrowth-in-Validated-Murine-Model-of-Alopecia-Areata-AA.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4187","ATI","ACRS","AA","BK4588","IE00B19Z4B17.USD","IE00B66KJ199.SGD","LU1878469433.USD","LU2065731478.USD","BK4153","BK4006","IE00B7SZL793.SGD","BK4007","IE0031619046.USD"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.aclaristx.com","stockEarnings":[{"period":"1week","weight":-0.1142},{"period":"1month","weight":-0.1823},{"period":"3month","weight":0.0141},{"period":"6month","weight":0.487},{"period":"1year","weight":0.4718},{"period":"ytd","weight":-0.0465}],"compareEarnings":[{"period":"1week","weight":-0.005},{"period":"1month","weight":-0.0136},{"period":"3month","weight":0.0038},{"period":"6month","weight":0.0635},{"period":"1year","weight":0.1725},{"period":"ytd","weight":0.006}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Aclaris Therapeutics, Inc. operates a clinical-stage biopharmaceutical company, develops novel drug candidates for immune-inflammatory diseases in the United States. It operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing innovative therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment offers laboratory services. The company develops Zunsemetinib, an MK2 inhibitor for the treatment of moderate to severe rheumatoid and Psoriatic arthritis, and Hidradenitis suppurativa; and ATI-1777, a soft JAK 1/3 inhibitor for the treatment of moderate to severe atopic dermatitis. It develops ATI-2138, an ITK/TXK/JAK3 inhibitor as a potential treatment for T cell-mediated autoimmune diseases; Gut-Biased Program for inflammatory bowel disease; and ATI-2231, an oral MK2 inhibitor for the treatment of pancreatic and metastatic breast cancer. Aclaris Therapeutics, Inc. was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.","yearOnYearQuotes":[{"month":1,"riseRate":0.363636,"avgChangeRate":0.145543},{"month":2,"riseRate":0.363636,"avgChangeRate":-0.038718},{"month":3,"riseRate":0.4,"avgChangeRate":-0.054834},{"month":4,"riseRate":0.4,"avgChangeRate":-0.010072},{"month":5,"riseRate":0.5,"avgChangeRate":-0.043272},{"month":6,"riseRate":0.6,"avgChangeRate":-0.004956},{"month":7,"riseRate":0.6,"avgChangeRate":0.009999},{"month":8,"riseRate":0.5,"avgChangeRate":-0.019617},{"month":9,"riseRate":0.4,"avgChangeRate":0.026634},{"month":10,"riseRate":0.4,"avgChangeRate":0.132278},{"month":11,"riseRate":0.363636,"avgChangeRate":0.075295},{"month":12,"riseRate":0.727273,"avgChangeRate":0.092435}],"exchange":"NASDAQ","name":"Aclaris Therapeutics","nameEN":"Aclaris Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Aclaris Therapeutics(ACRS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Aclaris Therapeutics(ACRS) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Aclaris Therapeutics,ACRS,Aclaris Therapeutics股票,Aclaris Therapeutics股票老虎,Aclaris Therapeutics股票老虎国际,Aclaris Therapeutics行情,Aclaris Therapeutics股票行情,Aclaris Therapeutics股价,Aclaris Therapeutics股市,Aclaris Therapeutics股票价格,Aclaris Therapeutics股票交易,Aclaris Therapeutics股票购买,Aclaris Therapeutics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Aclaris Therapeutics(ACRS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Aclaris Therapeutics(ACRS) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction